ABSTRACT
Light and active mobility, as well as multimodal mobility, could significantly contribute to decarbonization. Air quality is a key parameter to monitor the environment in terms of health and leisure benefits. In a possible scenario, wearables and recharge stations could supply information about a distributed monitoring system of air quality. The availability of low-power, smart, low-cost, compact embedded systems, such as Arduino Nicla Sense ME, based on BME688 by Bosch, Reutlingen, Germany, and powered by suitable software tools, can provide the hardware to be easily integrated into wearables as well as in solar-powered EVSE (Electric Vehicle Supply Equipment) for scooters and e-bikes. In this way, each e-vehicle, bike, or EVSE can contribute to a distributed monitoring network providing real-time information about micro-climate and pollution. This work experimentally investigates the capability of the BME688 environmental sensor to provide useful and detailed information about air quality. Initial experimental results from measurements in non-controlled and controlled environments show that BME688 is suited to detect the human-perceived air quality. CO2 readout can also be significant for other gas (e.g., CO), while IAQ (Index for Air Quality, from 0 to 500) is heavily affected by relative humidity, and its significance below 250 is quite low for an outdoor uncontrolled environment.
ABSTRACT
INTRODUCTION: It has been hypothesized that hyperoncotic colloids might contribute to acute kidney injury (AKI). However, the validity of this hypothesis remains unclear. METHODS: A meta-analysis was conducted of randomized controlled trials evaluating AKI after infusion of hyperoncotic albumin and hydroxyethyl starch (HES) solutions. Mortality was a secondary endpoint. Eligible trials were sought by multiple methods, and the pooled odds ratios (OR) for AKI and death and 95% confidence intervals (CI) were computed under a random effects model. RESULTS: Eleven randomized trials with a total of 1220 patients were included: 7 evaluating hyperoncotic albumin and 4 hyperoncotic HES. Clinical indications were ascites, surgery, sepsis and spontaneous bacterial peritonitis. Hyperoncotic albumin decreased the odds of AKI by 76% (OR, 0.24; CI, 0.12-0.48; P < 0.0001), while hyperoncotic HES increased those odds by 92% (OR, 1.92; CI, 1.31-2.81; P = 0.0008). Parallel effects on mortality were observed, with hyperoncotic albumin reducing the odds of death by 48% (OR, 0.52; CI, 0.28-0.95; P = 0.035) and hyperoncotic HES raising those odds by 41% (OR, 1.41; CI, 1.01-1.96; P = 0.043). CONCLUSIONS: This meta-analysis does not support the hypothesis that hyperoncotic colloid solutions per se injure the kidney. Renal effects appear instead to be colloid-specific, with albumin displaying renoprotection and HES showing nephrotoxicity.